Analyst Group comments on Chordate Medical’s Q4 report

Analyst Group has commented on Chordate Medical’s 2022 Q4 report. The analyst responsible confirms Anders Weilandt CEO Anders Weilandt’s view that the implementation and outcome of the migraine study is the single most important milestone in Chordate’s history. Now the company can fully focus on the final part of building the company; demonstrating Proof of Concept, i.e. measurable market share, that can lead to an exit.

Analyst Group highlights a transaction in which Pfizer is buying Biohaven Pharmaceutical:

“On May 10, 2022, Pfizer announced that it has entered into a definitive agreement to acquire Biohaven Pharmaceutical, which has developed the Nurtec ODT drug product, which is used for both acute migraine as well as prevention, where Pfizer itself expects to grow sales of Biohaven’s products to a peak sales level of $6 billion. We see this as clear evidence of the strategy of many large medtech and pharma players, i.e. that these players benefit more from acquiring smaller companies that have demonstrated proof of concept and have significant market potential, rather than developing innovative treatments themselves, in-house.”

Read the full analysis here.

More posts

For questions about Chordate’s share price or other investment-related topics, please see if the answer is here.

For questions about the medical effects of Ozilia® Migraine, please see if the answer is here.

To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.

Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company’s share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.

Contact us

  • This field is for validation purposes and should be left unchanged.

The information is handled according to our privacy policy